SyntekaBio Inc (226330) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SyntekaBio Inc (226330) has a cash flow conversion efficiency ratio of -0.169x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.01 Billion ≈ $-1.36 Million USD) by net assets (₩11.90 Billion ≈ $8.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SyntekaBio Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how SyntekaBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of SyntekaBio Inc for a breakdown of total debt and financial obligations.
SyntekaBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SyntekaBio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Koan Hao Technology Co Ltd
TWO:8354
|
0.014x |
|
Rompetrol Well
RO:PTR
|
0.020x |
|
Cuhadaroglu Metal Sanayi ve Pazarlama AS
IS:CUSAN
|
0.267x |
|
Chi Hua Fitness Co Ltd
TWO:1593
|
0.029x |
|
Neofect Co.Ltd
KQ:290660
|
-0.004x |
|
Bohae Brewery
KO:000890
|
0.023x |
|
iCRAFT Co. Ltd
KQ:052460
|
-0.181x |
|
American West Metals Ltd
AU:AW1
|
1.581x |
Annual Cash Flow Conversion Efficiency for SyntekaBio Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of SyntekaBio Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see SyntekaBio Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩24.94 Billion ≈ $16.90 Million |
₩-10.51 Billion ≈ $-7.12 Million |
-0.421x | -62.87% |
| 2023-12-31 | ₩31.23 Billion ≈ $21.16 Million |
₩-8.08 Billion ≈ $-5.47 Million |
-0.259x | +4.38% |
| 2022-12-31 | ₩31.46 Billion ≈ $21.32 Million |
₩-8.51 Billion ≈ $-5.77 Million |
-0.271x | -23.73% |
| 2021-12-31 | ₩27.63 Billion ≈ $18.72 Million |
₩-6.04 Billion ≈ $-4.09 Million |
-0.219x | -94.57% |
| 2020-12-31 | ₩41.54 Billion ≈ $28.15 Million |
₩-4.67 Billion ≈ $-3.16 Million |
-0.112x | -57.95% |
| 2019-12-31 | ₩46.11 Billion ≈ $31.25 Million |
₩-3.28 Billion ≈ $-2.22 Million |
-0.071x | +95.06% |
| 2018-12-31 | ₩1.64 Billion ≈ $1.11 Million |
₩-2.37 Billion ≈ $-1.60 Million |
-1.441x | -261.66% |
| 2017-12-31 | ₩-2.79 Billion ≈ $-1.89 Million |
₩-2.49 Billion ≈ $-1.69 Million |
0.891x | -- |
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more